Misplaced Pages

Kind Consumer: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 11:51, 7 November 2013 edit88.215.8.21 (talk) Commercialisation← Previous edit Revision as of 09:52, 18 November 2013 edit undoAnomieBOT (talk | contribs)Bots6,573,842 editsm Dating maintenance tags: {{Fact}}Next edit →
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
'''Kind Consumer Limited''' is a UK-based healthcare company which focuses on developing novel inhalation technologies to address some of the most significant global healthcare challenges. The company was founded in 2006 by ] a ] inventor and ] based in London<ref></ref><ref></ref><ref name = "realbusiness2"></ref> '''Kind Consumer Limited''' is a UK-based healthcare company which focuses on developing novel inhalation technologies to address some of the most significant global healthcare challenges. The company was founded in 2006 by ] a ] inventor and ] based in London<ref></ref><ref></ref><ref name = "realbusiness2"></ref>


== Inhaled Nicotine Delivery==
== Inhaled Nicotine Delivery - "A Safer Cigarette"<ref name = "realbusiness2" /><ref></ref><ref></ref> ==


=== The Technology === === The Technology ===


Kind Consumer's lead technology is a non-tobacco based medicinal ] inhalation device. The device is a non-electronic nicotine delivery platform that delivers an aerosol of nicotine formulation from a ]-like stick via a breath-operated valve for oral inhalation. The technology is based around the pharmaceutical design concepts of ]s. The valve has been designed to actuate at low inhalation flow rates similar to those of cigarette smoking. The inhaler contains no tobacco and does not involve combustion, electronics or heat of any nature in its operation.<ref></ref> Kind Consumer's lead technology is a non-tobacco based medicinal ] inhalation device. The device is a non-electronic nicotine delivery platform that delivers an aerosol of nicotine formulation from a ]-like stick via a breath-operated valve for oral inhalation. The technology is based around the pharmaceutical design concepts of ]s. The valve has been designed to actuate at low inhalation flow rates similar to those of cigarette smoking. The inhaler contains no tobacco and does not involve combustion, electronics or heat of any nature in its operation.{{fact|date=November 2013}}


The company is currently seeking a ] for the product from the UK's ]. The company is currently seeking a ] for the product from the UK's ].

Revision as of 09:52, 18 November 2013

Kind Consumer Limited is a UK-based healthcare company which focuses on developing novel inhalation technologies to address some of the most significant global healthcare challenges. The company was founded in 2006 by Alex Hearn a British inventor and entrepreneur based in London

Inhaled Nicotine Delivery

The Technology

Kind Consumer's lead technology is a non-tobacco based medicinal nicotine inhalation device. The device is a non-electronic nicotine delivery platform that delivers an aerosol of nicotine formulation from a cigarette-like stick via a breath-operated valve for oral inhalation. The technology is based around the pharmaceutical design concepts of metered-dose inhalers. The valve has been designed to actuate at low inhalation flow rates similar to those of cigarette smoking. The inhaler contains no tobacco and does not involve combustion, electronics or heat of any nature in its operation.

The company is currently seeking a marketing authorisation for the product from the UK's Medicines and Healthcare Products Regulatory Agency.

Product Development Rationale

The development rationale of inhaler technology is to provide a novel format of nicotine delivery which offers smokers a more acceptable alternative to the tobacco cigarette to help them cut down, substitute and quit - a concept known as Tobacco Harm Reduction.

The health burden of tobacco usage and in particular tobacco smoking is very well known. Tobacco smoking is a major global health epidemic with an estimated 1.3 billion individuals regularly smoking tobacco products across the world, predominantly cigarettes. It is well established that the key pharmacological element of tobacco addiction is the delivery of nicotine to the brain, leading to the release of a range of neurotransmitters such as dopamine which yield powerful feelings of “reward” and “pleasure” to the individual. The tobacco cigarette is a highly efficient nicotine delivery system that achieves rapid pulmonary delivery and sharp increases in the nicotine concentration in both arterial and venous blood. Although nicotine is the predominant addictive chemical in tobacco smoke, it is the other (approximately 4000) chemicals, including carcinogenic agents in the particulate phase, that lead to the well-established adverse health consequences of smoking. The World Health Organisation estimates that tobacco usage killed around 5.4 million people a year and by 2030 projections estimate this figure will rise to around 8.3 million deaths per year

Existing Regulatory Approved Nicotine Delivery Products

It has been argued that long-term success rates of existing NRT in smoking cessation remain low, with a recent study showing that only 6.75% of smokers receiving NRT therapy attained sustained abstinence for six months, albeit twice the rate of placebo treatment.

As an explanation for these findings it has been argued that the major limitation with delivery of nicotine by current nicotine replacement therapy products is that they do not provide smokers with the combination of a rapid delivery of nicotine and the unique respiratory tract sensory cues of inhaled nicotine (particularly upper airway irritation) which together are of primary importance in relieving craving for cigarettes. The nicotine nasal spray does achieve rapid delivery of nicotine but lacks the inhalational cues of cigarettes and has demonstrated limited acceptability due to the local irritant effects of nicotine on the nasal mucosa. The nicotine vapour Inhaler, although simulating the behavioural aspects of smoking and presenting some sensory cues, delivers nicotine very much slower than a cigarette.

Commercialisation

The technology is licensed for commercialisation to Nicoventures , a consumer healthcare company established by British American Tobacco to bring to market regulatory approved innovative nicotine delivery products. It is expected that the technology will be manufactured by the Bespak division of Consort Medical, a London Stock Exchange listed healthcare company

Notable Investors

Kind Consumer has attracted investment from a number of notable high profile angel investors including:

References

  1. Start Uploaded (2011) - Alex Hearn introduces Kind Consumer
  2. realbusiness (2011) -Alex Hearn: entrepreneur with “soul”
  3. ^ realbusiness (2011) - Idea of the week: the healthy cigarette
  4. The Independent newspaper (2011) - Revolution in smoking aims to stub out cigarettes – with the help of tobacco firms
  5. ^ WHO (2007) - Gender and Tobacco Control: A Policy Brief
  6. ^ Royal College of Physicians (2007) Harm reduction in Nicotine Addiction: Helping People who Can't Quit. A report by the Tobacco Advisory Group of the Royal College of Physicians
  7. Moore et al. (2009) - Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis, BMJ, Vol. 338, No. 7699, Apr. 11, 2009
  8. Rose (1988) - The role of upper airway stimulation in smoking Prog Clin Biol Res. 1988;261:95-106.
  9. ^ Schneider et al. 1996 - Clinical Pharmacokinetics of Nasal Nicotine Delivery A review and comparison to other nicotine systems, Clin Pharmacokinet. 1996 Jul;31(1):65-80
  10. Nicoventures Limited homepage.
  11. http://www.tobaccojournal.com/BAT_unit_to_market__innovative__nicotine_inhaler.50583.0.html Tobacco Journal International (2011)]
  12. Guardian (2012) - Consort Medical climbs after deal with British American Tobacco for safer smoking product
  13. Kind Consumer Website (2013) - History
  14. Express newspaper (2011) - Sir Terry Leahy’s nicotine fix
  15. The Independent newspaper(2011) - Leahy invests in 'safe' tobacco (after Tesco made a killing on cigarettes)
Categories: